Pharmacokinetic Genes Do Not Influence Response or Tolerance to Citalopram in the STAR*D Sample

Abstract

No genetic polymorphism in the pharmacokinetic genes examined was significantly associated with our response or tolerance phenotypes in both stages. For managing pharmacological treatment with citalopram, routine screening of the common pharmacokinetic DNA variants that we examined appears to be of limited clinical utility.